An AI-powered MRI analysis tool that quantifies cellular-level brain changes to enable early detection and monitoring of Alzheimer's disease and other…
Darmiyan's BrainSee applies patented AI and machine learning to standard clinical MRI scans to measure microscopic changes in the spaces between brain cells at the voxel level without requiring specialized hardware. The technology provides five-year prognoses for patients with mild cognitive impairment, generates focal degeneration maps, and tracks patient-specific responses to interventions. It is designed for seamless integration into clinical workflows and aims to cut Alzheimer's detection to years before symptom onset. BrainSee is a product of Darmiyan.